此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Diabetes Risk Diagnosis and Management (DIARIO)

2022年1月11日 更新者:Licia Iacoviello、Neuromed IRCCS

Early Diagnosis and Management of Patients at Risk for Diabetes

Considering the multifactorial nature of the complications of Type 2 diabetes, such as cardiovascular and neurological complications and therefore the multiplicity of risk factors that contribute to their development, it is assumed that the use of a dedicated function of the MyStar Connect software (beta version), that allows the querying of the application through specific queries (presence of risk factors) and the calculation of specific risk scores in order to extract the patients most at risk of developing such complications, can provide support to the diabetologist to optimize management of the patient at risk and complicated through, for example, a more intensive visit program and this then translates into an improvement in the parameters related to these risk factors.

研究概览

详细说明

The study aims are:

  • To evaluate the percentage of subjects at risk of diabetes in the general population
  • To evaluate the percentage of type 2 diabetics with and without complications in the identified population at risk
  • To evaluate whether the new computer system is able to identify subjects at risk of developing complications or aggravation of complications already in progress (cardiovascular and neurological complications).

Through the IT platform made available within the framework of the project, the selected sample will be given the questionnaire to detect the risk of diabetic disease (FINDRISC adapted) and, in the case of a positive outcome, the subject at risk will be assessed with laboratory tests, to confirm or not the condition of prediabetes or diabetes. Therefore, all the subsequent phases of patient care and management will be followed, from the modification of lifestyles for prediabetics to the management of overt diabetic pathology and the complications associated with it, thus experimenting with all the modules of the software platform integrated.

Subjects who have a high diabetic risk score will be referred to the Neuromed laboratories for the analysis of fasting blood glucose and the glycemic load test. Consistent with the diagnostic protocol developed, the subjects will follow a triple address:

  1. Subjects at risk with fasting blood glucose or normal glycemic load
  2. Subjects with prediabetes
  3. Subjects with diabetes Patients in whom a vascular or neurological complication is diagnosed will be managed by the Neuromed clinic work groups using dedicated modules developed within the project.

At time T0 for diabetic patients without or with cardiovascular and neurological complications who will come to visit as from normal clinical practice, the presence of risk / complication parameters will be checked and risk scores will be applied to ascertain the patient's condition. The patient will then be followed as per normal clinical practice and risk parameters and the derived scores will be re-evaluated.

研究类型

观察性的

注册 (实际的)

1500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • IS
      • Pozzilli、IS、意大利、86077
        • IRCCS INM Neuromed, Department of Epidemiology and Prevention

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

34年 至 100年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Consecutive male and female subjects, over 34 years of age recruited in teh framework of the recall phase of the Moli-sani study.

Male and Female patients with type 2 diabetes without or with cardiovascular or neurological complications

描述

Inclusion Criteria:

  • Signature of informed consent;
  • Subjects recruited consecutively during the recall phase of the Moli-sani project.
  • Patients with type 2 diabetes mellitus and vascular or neurological complications attending the IRCCS Neuromed

Exclusion Criteria:

  • Inability to understand and to want
  • Refusal to sign informed consent.
  • Type 1 diabetes
  • Gestational diabetes.
  • For subjects of the general population, a previous diagnosis of diabetes.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:仅案例
  • 时间观点:横截面

队列和干预

团体/队列
干预/治疗
General population
Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
其他名称:
  • MyStar Connect software (version beta)
Patients with type 2 Diabetes
Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of subjects at high risk for Diabetes
大体时间:12 months
Risk for type 2 diabetes measured by a structured questionnaires with 11 questions scoring from -1 to 27 and classified in 5 risk categories: Low risk (score>6); Low-medium risk (score 7-11); Medium-high risk (score 12-14); high risk (score 15-20); very high risk (score >20).
12 months
Number of subjects with diabetes
大体时间:18 months
diabetes diagnosis will be based on fasting plasma glucose (FPG)≥126 mg/dl. The testswill be performed in a laboratory using a certified method. Fasting is defined as no caloric intake for at least 8 h.
18 months
Concentration of glucose in plasma
大体时间:24 months
Glucose control in patients with diabetes and cardiovascular or neurological complications, measured with plasma glucose criteria, defined as FPG <126 mg/dL (7.0 mmol/L).
24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Licia Iacoviello, MD, PhD、IRCCS Neuromed

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年1月9日

初级完成 (实际的)

2021年7月30日

研究完成 (实际的)

2021年12月31日

研究注册日期

首次提交

2019年5月9日

首先提交符合 QC 标准的

2019年5月11日

首次发布 (实际的)

2019年5月14日

研究记录更新

最后更新发布 (实际的)

2022年1月12日

上次提交的符合 QC 标准的更新

2022年1月11日

最后验证

2022年1月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅